StudyGraphics #VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma February 18, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract Using pegylated liposomal doxorubicin as maintenance therapy shows disease improvement in patients with mycosis fungoides #VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma #VisualAbstract: Perioperative oxiplatin with S-1 significantly improves survival in patients with advanced gastric cancer or gastroesophageal adenocarcinoma undergoing D2 gastrectomy
